A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer
- Status
- COMPLETED
- Phase
- NA
Clinical Trials Related to Ipilimumab
Related studies linked through entity extraction aliases.
Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
- Status
- COMPLETED
- Phase
- PHASE1
Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- COMPLETED
- Phase
- PHASE2
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- COMPLETED
- Phase
- PHASE3
Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases
- Status
- COMPLETED
- Phase
- N/A
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
- Status
- TERMINATED
- Phase
- PHASE1
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
- Status
- TERMINATED
- Phase
- PHASE1
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases
- Status
- COMPLETED
- Phase
- PHASE2
Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2